会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NUCLEOTIDE ANALOGS
    • 核素类似物
    • WO1998004569A1
    • 1998-02-05
    • PCT/US1997013244
    • 1997-07-25
    • GILEAD SCIENCES, INC.
    • GILEAD SCIENCES, INC.ARIMILLI, Murty, N.CUNDY, Kenneth, C.DOUGHERTY, Joseph, P.KIM, Choung, U.OLIYAI, RezaSTELLA, Valentino, J.
    • C07F09/6561
    • C07F9/65616C07F9/6512
    • Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R )2OC(O)X(R)a, wherein R independently is H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR in which R is C1-C12 alkyl; X is N or O; R is independently H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, -O-, -N=, -NR -, -N(R )2- or OR , R independently is -H or C1-C8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR . The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.
    • 提供新的化合物,其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC(R 2)2 OC(O)X(R)a的碳酸酯和/或氨基甲酸酯的酯,其中R 2独立地是H,C1- C 2 -C 12烷基,芳基,烯基,炔基,烷基芳基,炔基芳基,烷芳基,芳基炔基,芳基烯基或芳烷基,其未被取代或被卤素,叠氮基,硝基或OR 3取代,其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H,C 1 -C 12烷基,芳基,烯基,炔基,链烯基芳基,炔基芳基,烷芳基,芳基炔基,芳基烯基或芳基烷基,其未被取代或被卤素,叠氮基,硝基,-O - , - N = 4, - (R 4)2 - 或OR 3,R 4独立地是-H或C 1 -C 8烷基,条件是至少一个R不是H; 和a为1或2,条件是当a为2且X为N时,(a)两个R基团可以一起形成碳环或含氧杂环,或(b)一个R另外可以是OR <3>。 该化合物可用作制备抗病毒化合物或寡核苷酸的中间体,或可用于直接给患者施用抗病毒治疗或预防。 当口服给药时,实施方案特别有用。
    • 10. 发明申请
    • APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING
    • 生物分子的APTAMER特异性和制备方法
    • WO1992014843A1
    • 1992-09-03
    • PCT/US1992001383
    • 1992-02-21
    • GILEAD SCIENCES, INC.TOOLE, John, J.GRIFFIN, Linda, C.BOCK, Louis, C.LATHAM, John, A.MUENCHAU, Daryl, DeanKRAWCZYK, Steven
    • GILEAD SCIENCES, INC.
    • C12Q01/68
    • C12N15/115C12N2310/16C12N2310/315C12N2310/318C12N2310/33C12N2310/332C12N2310/335G01N2333/974
    • A method for identifying oligomer sequences which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described. The method is used to generate aptamers that bind to serum Factor X, thrombin, bradykinin, PGF2 alpha and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for therapeutic and diagnostic purposes.
    • 描述了用于鉴定特异性结合目标分子如血清蛋白,激肽,类二十烷酸和细胞外蛋白的寡聚物序列的方法。 该方法用于产生与血清因子X,凝血酶,缓激肽,PGF2α和细胞表面分子结合的适体。 该技术涉及将靶分子与含有随机序列和序列的寡核苷酸的混合物络合,所述随机序列和序列用作PCR引物的条件,其中用特异性结合序列形成复合物,但不与寡核苷酸混合物的其它成员形成。 然后将复合物与未络合的寡核苷酸分离,并使用聚合酶链反应从分离的复合物中回收寡核苷酸混合物的络合成员。 可以对回收的寡核苷酸进行测序,并且可以使用使用络合,分离,扩增和回收的连续轮次选择。 寡核苷酸可用于治疗和诊断目的。